• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Alessandro Riva - Articles and news items

Novartis

Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

Industry news / 6 May 2014 / Novartis

Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control…

Novartis

Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways

Industry news / 4 April 2014 / Novartis

Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research…

Novartis

Novartis announces positive Phase III study for Jakavi® in patients with rare blood cancer polycythemia vera

Industry news / 7 March 2014 / Novartis

Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control…

Novartis

Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma

Industry news / 19 February 2014 / Novartis

Novartis announced that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment…

Novartis logo

Hervé Hoppenot, President of Novartis Oncology, leaves Novartis to pursue career opportunity outside of organization

Industry news / 12 January 2014 / Novartis

Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect…

Novartis logo

Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study

Industry news / 6 December 2013 / Novartis

LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma…

Novartis logo

Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival

Industry news, News / 7 August 2013 / Novartis

Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib…

Novartis logo
Novartis logo
Novartis logo
Novartis logo
Novartis logo

Novartis drug Exjade® first treatment approved by FDA

Industry news, News / 23 January 2013 / Novartis

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +